INTELLIA THERAPEUTICS, INC. (NTLA) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $14.00K; Additional Paid in Capital, Common StockUSD $3.52B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.03M; Retained Earnings (Accumulated Deficit)USD $-2.79B.
- 2026-03-31: Common Stock, Value, IssuedUSD $12.00K; Additional Paid in Capital, Common StockUSD $3.31B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-240.00K; Retained Earnings (Accumulated Deficit)USD $-2.69B.
- 2025-12-31: Common Stock, Value, IssuedUSD $12.00K; Additional Paid in Capital, Common StockUSD $3.26B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $1.03M; Retained Earnings (Accumulated Deficit)USD $-2.59B.
- 2025-09-30: Common Stock, Value, IssuedUSD $12.00K; Additional Paid in Capital, Common StockUSD $3.24B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $990.00K; Retained Earnings (Accumulated Deficit)USD $-2.49B.
INTELLIA THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $14.00K | $3.52B | $-1.03M | $-2.79B | $727.71M | 3 month · $18.07M | (m) | (m) |
| 2026-03-31 | $12.00K | $3.31B | $-240.00K | $-2.69B | $620.94M | 3 month · $13.48M | (m) | (m) |
| 2025-12-31 | $12.00K | $3.26B | $1.03M | $-2.59B | $671.39M | 12 month · $80.22M | (m) | (m) |
| 2025-09-30 | $12.00K | $3.24B | $990.00K | $-2.49B | $748.42M | 3 month · $19.60M | (m) | (m) |
| 2025-06-30 | $10.00K | $3.11B | $653.00K | $-2.39B | $-715.25M | 3 month · $22.04M | (m) | (m) |
| 2025-03-31 | $10.00K | $3.07B | $1.06M | $-2.29B | $779.92M | 3 month · $21.84M | (m) | (m) |
| 2024-12-31 | $10.00K | $3.05B | $605.00K | $-2.18B | $871.96M | 12 month · $154.27M | (m) | (m) |
| 2024-09-30 | $10.00K | $3.01B | $3.30M | $-2.05B | $962.62M | 3 month · $39.62M | (m) | (m) |
| 2024-06-30 | $10.00K | $2.88B | $-1.16M | $-1.91B | $971.06M | 3 month · $40.86M | (m) | (m) |
| 2024-03-31 | $10.00K | $2.80B | $-947.00K | $-1.77B | $1.04B | 3 month · $34.18M | 3 month · $2.13M | (m) |
| 2023-12-31 | $9.00K | $2.71B | $-2.26M | $-1.66B | $1.05B | 12 month · $134.05M | (m) | (m) |
| 2023-09-30 | $9.00K | $2.57B | $-3.57M | $-1.53B | $1.04B | 3 month · $35.35M | (m) | 3 month · $81.00K |
| 2023-06-30 | $9.00K | $2.51B | $-3.87M | $-1.40B | $1.10B | 3 month · $36.40M | (m) | (m) |
| 2023-03-31 | $9.00K | $2.47B | $-2.68M | $-1.28B | $1.19B | 3 month · $27.25M | (m) | 3 month · $62.00K |
| 2022-12-31 | $9.00K | $2.42B | $-7.46M | $-1.18B | $1.24B | 12 month · $91.40M | (m) | (m) |
| 2022-09-30 | $8.00K | $1.90B | $-9.37M | $-1.06B | $824.95M | 3 month · $25.21M | (m) | 3 month · $54.00K |
| 2022-06-30 | $8.00K | $1.84B | $-9.55M | $-950.55M | $880.55M | 3 month · $23.07M | (m) | (m) |
| 2022-03-31 | $8.00K | $1.81B | $-8.06M | $-849.87M | $953.75M | 3 month · $18.49M | (m) | 3 month · $164.00K |
| 2021-12-31 | $7.00K | $1.75B | $-2.63M | $-703.00M | $1.04B | 12 month · $47.01M | (m) | (m) |
| 2021-09-30 | $7.00K | $1.73B | $-174.00K | $-621.76M | $1.11B | 3 month · $15.41M | (m) | 3 month · $284.00K |
| 2021-06-30 | $7.00K | $1.04B | $-13.00K | $-550.12M | $494.81M | 3 month · $10.61M | (m) | (m) |
| 2021-03-31 | $7.00K | $1.03B | $-12.00K | $-481.31M | $545.87M | 3 month · $6.42M | (m) | 3 month · $52.00K |
| 2020-12-31 | $7.00K | $962.17M | $1.00K | $-435.11M | $527.07M | 12 month · $19.90M | (m) | (m) |
| 2020-09-30 | $6.00K | $722.50M | $31.00K | $-392.92M | $329.62M | 3 month · $5.40M | (m) | (m) |
| 2020-06-30 | $6.00K | $716.50M | $155.00K | $-365.08M | $351.59M | 3 month · $4.76M | (m) | (m) |
| 2020-03-31 | $5.00K | $580.07M | $373.00K | $-332.68M | $247.76M | 3 month · $4.16M | (m) | 3 month · $48.00K |
| 2019-12-31 | $5.00K | $570.49M | $261.00K | $-300.88M | $269.88M | 12 month · $15.09M | (m) | (m) |
| 2019-09-30 | $5.00K | $547.91M | $336.00K | $-272.60M | $275.65M | 3 month · $3.08M | (m) | 3 month · $199.00K |
| 2019-06-30 | $5.00K | $525.57M | $255.00K | $-248.97M | $276.87M | 3 month · $4.40M | (m) | 3 month · $3.00K |
| 2019-03-31 | $5.00K | $487.56M | $59.00K | $-223.28M | $264.34M | 3 month · $4.59M | (m) | 3 month · $120.00K |
| 2018-12-31 | $5.00K | $478.97M | $-28.00K | $-201.03M | $277.92M | 12 month · $17.05M | (m) | (m) |
| 2018-09-30 | $4.00K | $445.23M | (m) | $-181.96M | $263.27M | 3 month · $4.46M | (m) | (m) |
| 2018-06-30 | $4.00K | $438.59M | (m) | $-159.26M | $279.34M | 3 month · $4.90M | (m) | (m) |
| 2018-03-31 | $4.00K | $432.53M | (m) | $-137.04M | $295.50M | 3 month · $4.11M | (m) | (m) |
| 2017-12-31 | $4.00K | $421.71M | (m) | $-121.11M | $300.60M | 12 month · $15.32M | (m) | (m) |
| 2017-09-30 | $4.00K | $272.99M | (m) | $-97.15M | $175.85M | (m) | (m) | (m) |
| 2017-06-30 | $4.00K | $269.38M | (m) | $-81.79M | $187.59M | (m) | (m) | (m) |
| 2017-03-31 | $4.00K | $266.08M | (m) | $-66.20M | $199.88M | (m) | (m) | (m) |
| 2016-12-31 | $4.00K | $263.40M | (m) | $-53.57M | $209.84M | 12 month · $6.71M | (m) | (m) |
| 2016-09-30 | $4.00K | $261.13M | (m) | $-43.01M | $218.12M | 9 month · $4.70M | (m) | 9 month · $3.37M |
| 2016-06-30 | $4.00K | $259.12M | (m) | $-35.52M | $223.60M | 6 month · $2.65M | (m) | 6 month · $3.32M |
| 2016-03-31 | $0.00 | $1.48M | (m) | $-28.62M | $-27.14M | (m) | (m) | (m) |
| 2015-12-31 | $0.00 | $735.00K | (m) | $-21.94M | $-21.20M | 12 month · $685.00K | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | $7.57M | 8 month · $308.00K | (m) | (m) |
| 2014-05-06 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |